(Healthday)—The U.S. Food and Drug Administration’s controversial approval of a new Alzheimer’s drug, along with its high price, is now being investigated by two House committees.
(Healthday)—The U.S. Food and Drug Administration’s controversial approval of a new Alzheimer’s drug, along with its high price, is now being investigated by two House committees.